{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T09:41:41Z","timestamp":1697276501479},"reference-count":64,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2007,2,28]],"date-time":"2007-02-28T00:00:00Z","timestamp":1172620800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2007,5]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background<\/jats:bold> Although reversal of pretransplant renal dysfunction in hepatorenal syndrome reduces post\u2010transplant complications, the overall impact on morbidity and mortality requires clarification.<\/jats:p><jats:p><jats:bold>Aim<\/jats:bold> To review trials of pharmacologic interventions in hepatorenal syndrome, with specific assessment of trial quality and study endpoints, including patient survival and renal outcome measures.<\/jats:p><jats:p><jats:bold>Methods<\/jats:bold> Literature search and selection was carried out by a single reviewer. Data extraction and quality analysis were carried out by two independent reviewers.<\/jats:p><jats:p><jats:bold>Results<\/jats:bold> Of 848 identified articles, 36 were eligible for inclusion. Twenty\u2010one were full\u2010text. Only 19% were randomized\u2010controlled trials. About 50% of studies included only Type 1 hepatorenal syndrome patients. Serum creatinine, urine output and urine sodium were the most common renal outcome measures. Only 42% defined a primary renal endpoint. About 88% of articles reported mortality rates.<\/jats:p><jats:p><jats:bold>Conclusions<\/jats:bold> Existing literature of pharmacologic agents for use in hepatorenal syndrome is limited by poor study design, including non\u2010randomization, heterogeneous study populations, lack of power, and limited use of clinically relevant outcomes. There is insufficient information in most trials to judge the impact of pharmacologic therapy on mortality or rates of transplantation. The validity of renal outcome measures as surrogate markers of more clinically relevant endpoints has not been established.<\/jats:p>","DOI":"10.1111\/j.1365-2036.2007.03303.x","type":"journal-article","created":{"date-parts":[[2010,7,23]],"date-time":"2010-07-23T11:12:29Z","timestamp":1279883549000},"page":"1017-1028","source":"Crossref","is-referenced-by-count":5,"title":["Systematic review: renal and other clinically relevant outcomes in hepatorenal syndrome trials"],"prefix":"10.1111","volume":"25","author":[{"given":"P.","family":"TANDON","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V. G.","family":"BAIN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. T.","family":"TSUYUKI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"KLARENBACH","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,2,28]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510230122"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(93)90031-7"},{"key":"e_1_2_7_4_2","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/0016-5085(87)90327-1","article-title":"Effects of renal impairment on liver transplantation","volume":"93","author":"Rimolo A","year":"1987","journal-title":"Gastro"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199502150-00010"},{"key":"e_1_2_7_6_2","first-page":"159","article-title":"Pretransplant renal dysfunction predicts poorer outcome in liver transplantation","volume":"48","author":"Lafayette RA","year":"1997","journal-title":"Clin Nephrol"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026698001921"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50276"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(93)90963-D"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510280407"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(02)80037-X"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510290629"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20262"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197311292892201"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510270107"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(97)80456-4"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2003.09.019"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2003.10.024"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(05)81618-6"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.03086.x"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(95)00134-4"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(04)90224-3"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(03)80588-3"},{"key":"e_1_2_7_24_2","first-page":"694A","article-title":"A prospective, randomized, double\u2010blind placebo\u2010controlled trial of terlipressin for type 1 hepatorenal syndrome (HRS)","volume":"44","author":"Sanyal A","year":"2006","journal-title":"Hepatology"},{"key":"e_1_2_7_25_2","first-page":"449A","article-title":"Noradrenaline versus terlipressin in the treatment of Type 1 hepatorenal syndrome: a randomized controlled trial","volume":"44","author":"Sharma P","year":"2006","journal-title":"Hepatology"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1746.2003.02934.x"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(98)80151-7"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(02)80924-2"},{"key":"e_1_2_7_29_2","first-page":"542A","article-title":"Octreotide, midodrine, and albumin, triple therapy is effective in reversing hepatorenal syndrome","volume":"34","author":"Hassanein TI","year":"2001","journal-title":"Hepatology"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(03)80575-5"},{"key":"e_1_2_7_31_2","first-page":"636","article-title":"Ornipressin and\/or misoprostol improve renal disturbances but do not change final outcome of hepatorenal syndrome","volume":"26","author":"VanderMerwe S","year":"1997","journal-title":"Hepatology"},{"key":"e_1_2_7_32_2","first-page":"A1276","article-title":"Ornipressin \u2013 a promising option for the treatment of hepatorenal syndrome in liver cirrhosis patients","volume":"112","author":"Gunther R","year":"1997","journal-title":"Gastroenterology"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(03)83364-4"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(02)80155-6"},{"key":"e_1_2_7_35_2","first-page":"539A","article-title":"Treatment of hepatorenal syndrome with albumin and diuretics tailored to central venous pressure","volume":"34","author":"Laurent G","year":"2001","journal-title":"Hepatology"},{"key":"e_1_2_7_36_2","first-page":"78","article-title":"Terlipressin and gelafundin: safe therapy of hepatorenal syndrome","volume":"2","author":"Saner FH","year":"2004","journal-title":"Eur J Med Res"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)74933-3"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510300430"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(99)80025-7"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.34343"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(00)80158-0"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.1999.00556.x"},{"key":"e_1_2_7_43_2","first-page":"15","article-title":"Long term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study","volume":"64","author":"Mulkay JP","year":"2001","journal-title":"Acta Gastroenterol Belg"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.00271.x"},{"key":"e_1_2_7_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2000.03214.x"},{"issue":"1","key":"e_1_2_7_46_2","first-page":"A1111","article-title":"Terlipressin therapy for hepatorenal syndrome \u2013 which patients should be treated","volume":"40","author":"Gow PJ","year":"2004","journal-title":"Hepatology"},{"issue":"1","key":"e_1_2_7_47_2","first-page":"646A","article-title":"Terlipressin for renal failure in cirrhosis. A single centre review","volume":"40","author":"Triantos CK","year":"2004","journal-title":"Hepatology"},{"key":"e_1_2_7_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(03)83625-9"},{"key":"e_1_2_7_49_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.32364"},{"key":"e_1_2_7_50_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh930"},{"key":"e_1_2_7_51_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200202000-00009"},{"key":"e_1_2_7_52_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1746.2002.02816.x"},{"issue":"2","key":"e_1_2_7_53_2","first-page":"103","article-title":"Terlipressin and albumin combination treatment in hepatorenal syndrome","volume":"50","author":"Danalioglu A","year":"2003","journal-title":"Hepatogastroenterology"},{"key":"e_1_2_7_54_2","doi-asserted-by":"publisher","DOI":"10.1215\/15228517-1-4-282"},{"key":"e_1_2_7_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(99)80324-0"},{"key":"e_1_2_7_56_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/84.6.407"},{"key":"e_1_2_7_57_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.8.771"},{"key":"e_1_2_7_58_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-125-7-199610010-00011"},{"key":"e_1_2_7_59_2","doi-asserted-by":"publisher","DOI":"10.1208\/aapsj080117"},{"key":"e_1_2_7_60_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199103213241201"},{"key":"e_1_2_7_61_2","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/archinte.1994.00420020117013","article-title":"Limitations of the serum creatinine level and creatinine clearance as filtration markers in cirrhosis","volume":"154","author":"Caregaro L","year":"1994","journal-title":"Arch Intern Med"},{"key":"e_1_2_7_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(87)90156-2"},{"key":"e_1_2_7_63_2","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2003.50035"},{"key":"e_1_2_7_64_2","first-page":"342","article-title":"Glomerular filtration rate measurement in cirrhotic patients with renal failure","volume":"50","author":"Roy L","year":"1998","journal-title":"Clin Nephrol"},{"key":"e_1_2_7_65_2","first-page":"341","article-title":"Evaluation of measured and calculated creatinine clearances as glomerular filtration markers in different stages of liver cirrhosis","volume":"51","author":"Orlando R","year":"1999","journal-title":"Clin Nephrol"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2007.03303.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2007.03303.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T21:24:25Z","timestamp":1697232265000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2007.03303.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2,28]]},"references-count":64,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["10.1111\/j.1365-2036.2007.03303.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2007.03303.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,2,28]]}}}